Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


nextgennicotine2017-header.jpg

Programme

The agenda for the 2017 Next Generation Nicotine Delivery conference has been developed through extensive research across the sector, and we are proud to publish this year’s long awaited programme below.

For further information you can contact our team on:

David Jones
Programme Director
Email:david.jones@arena-international.com
Telephone: +44 (0) 207 936 6645

Overview

    • 08:20 - 08:35
      • Registration & Refreshments

      • 08:45 - 09:15
        • Speaker

          Ian Jones – VP Reduced-Risk Products, JTI

        Opening Keynote: Evaluating Past, Present And Future Of Tobacco Harm Reduction

        • Understanding what is ‘tobacco harm reduction’, why is this important

        • Considering its overall history, a review of different products

        • Predicting the future, what will tobacco harm reduction look like in the future

        • Incorporating Ploom Tech, a brief introduction to its technology

      • 09:15 - 09:55
      • Determining The Impact Of The FDA’s Stance On Nicotine Containing Products

        • Nicopure point of view, where do we see the US market in 5 years?

        • Learning about Nicopure and Right to be Smoke-Free Coalition's court proceedings against the FDA, an update on how this is progressing

        • Considering the impact of the Trump Administration’s pro-deregulation stance on existing tobacco regulations, the opportunities this may present

        • How will FDA’s new comprehensive tobacco regulatory plan affect vape businesses and the e-cigarette industry?

        • Assessing how the US market has changed so far, has this lead to reduced innovation and opportunity?

      • 09:55 - 10:25
        • Speaker

          Robert Morrison – Senior Regulatory Policy Executive, Committee of Advertising Practice

        Understanding Advertising Standards For E-Cigarettes

        • Reviewing the CAP and BCAP’s consultation on health claims, what can and can’t be advertised

        • Sharing recent, and relevant ASA rulings on e-cigarette ads, what this means for the sector?

      • 10:25 - 10:40
      • Label Challenges And Solutions For The E-Liquid Market

        • Addressing industry wide challenges on vape labelling

        • Introducing digital label solutions

      • 10:40 - 11:10
        • Morning Refreshments & Networking

        • 11:10 - 12:40
        • Interactive Roundtables

          Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Hosted by industry experts and each focused on a single issue, roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.

          Each roundtable session lasts for 45 minutes, and delegates may attend up to 2 roundtables

          • Discussing The Need And Consequences Of Independent Interoperability Related To The TPD Dr. Marietta Ulrich-Horn – Speaker

          • Discussing The Variance Of TPD Implementation In Different EU Member States Manon Ombredane – Speaker

          • How will REACH and CLP regulations affect the pure nicotine based products in 2018? Marcin Górecki – Speaker

          • Subject To Be Determined Dr Jaydene Halliday – Speaker

          • What Do Consumers Want? – Reviewing Devices & E-Liquids Graham McGee – Speaker

        • 12:40 - 13:30
          • Lunch & Networking

          • 13:30 - 14:15
          • Panel: Stuck In The Middle Of Regulation, Opinion Leaders, Media and HCPs: Understanding The Role Of Clinical Trials To Drive The Success Of New Nicotine Products

            Setting the scene: Innovative products for novel forms of nicotine consumption are entering the market. Be it e-cigarettes or tobacco heating systems (heat-not-burn), consumers often hope for harm reduction compared to continuing to smoke conventional cigarettes.

            There is an ongoing debate among healthcare professionals (HCPs) and their medical associations about the potential benefits and risks of new nicotine products. Additionally, the regulatory requirements of the EU’s Tobacco Product Directive (TPD) and the FDA's New Tobacco Regulations have to be considered.

            This panel session will discuss/ debate:

            • Appreciating whether we will see a boom of clinical trials in the near future due to the dynamically changing market

            • Respecting what needs to be taken into account when conducting a clinical trial in the area of “cessation or substitution of conventional smoking”

            • Recognising whether European regulatory authorities ready to handle the increasingly large scientific dossiers submitted provided by the industry?

            • Reviewing who has a role to play in making new nicotine products and tobacco harm reduction a success

          • 14:15 - 14:45
          • Delving Deeper Into The Role Of A E-Liquid Label Supplier

            • Recognising the importance of continual material innovation to meet future demands

            • Determining future counterfeit challenges to understand how Label Solutions are innovating to address these

            • Divulging the scientific material adaptations needed to create durable yet aesthetically pleasing labels

          • 14:45 - 15:15
            • Speaker

              Richard Hyslop – Chief Executive, Independent British Vape Trade Association (IBVTA)

            Navigating The European Commission’s Public Consultation On Taxation

            • Reviewing the legacy tobacco excise regulation, should this be adopted for vaping

            • Investigating what’s happened during the European Commission’s consultation so far, the results

            • Analysing different EU member state’s tax on vaping, is there a need for standardisation

            • Lobbying in the future, how the IBVTA is leading the fight

          • 15:15 - 15:30
            • Speaker

              Scott Fletcher – Managing Director, Hall Analytical Laboratories

            What Do The FDA’s PMTA Requirements For Extractable & Leachable Mean For You?

            • Understanding the PMTA’s requirements for extractable and leachables, why is this important to consider now

            • Reviewing the MHRA’s stance on extractable and leachables, how is this influenced by the US

            • Analysing the pitfalls and what you need to consider in the future

          • 15:30 - 16:00
            • Afternoon Refreshments & Networking

            • 16:00 - 16:30
            • CORESTA’s Contribution To Develop Standards For The Global Vapor Industry

              • Understanding CORESTA is, it’s members and an overview of work carried out

              • Learning about CORESTA’s E-Vapor Sub-Group

              • Introducing the development of CRM, why is this important?

              • Establishing CORESTA’s work to introduce standards to understand the importance

            • 16:30 - 16:45
            • Evaluating UKVIA’s Expectation For The TPD Post Britain Leaving The EU

              • Lobbying for changes to existing regulation, what UKVIA are doing and why?

              • Reviewing the opportunity Brexit presents for UK manufacturers and retailers to alter existing regulation

              • Identifying post Brexit regulatory challenges to foresee what 2019-onwards European trade will look like

              • Predicting what post Brexit Britain will look like, to ensure continued trade into European states

          previousnext